Form 8-K Sarepta Therapeutics, For: Sep 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Sarepta Therapeutics (SRPT) Appoints Edward Kaye as Permanent CEO; Updates on Exec Team
September 21, 2016 8:41 AM EDTSarepta Therapeutics (Nasdaq: SRPT) disclosed the following in a U.S. SEC filing on Wednesday morning:
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On September 20, 2016, the Board of Directors (the Board) of Sarepta Therapeutics, Inc. (the Company) appointed Edward M. Kaye, M.D. as President and Chief Executive Officer (CEO) of the Company and to serve as a member of the Board. Dr. Kaye will continue in his role as Chief Medical Officer, a role which he has held since June 2011. Prior to his new... More
